8-K: INVO Fertility Q2 2025: Revenue Up, Net Loss Widens

INVO Fertility, Inc. reported a 1% revenue increase to a record $1.86 million in Q2 2025, alongside a widened net loss of $3.2 million and an increased Adjusted EBITDA loss.

Summary

• Total revenue for Q2 2025 was $1,863,654, a 1% increase compared to $1,836,597 in Q2 2024, marking a new quarterly record.
• Consolidated clinic revenue increased 1% to $1,832,094 from $1,807,921 in Q2 2024.
• Revenue from all clinics, including both consolidated and equity method clinics, increased 2% to $2,188,893 compared to $2,141,229 in Q2 2024.
• Net loss from continuing operations widened to $(3.2) million in Q2 2025 from $(2.2) million in Q2 2024.
• Adjusted EBITDA loss increased to $(587,230) in Q2 2025 compared to $(509,623) in Q2 2024.
• An impairment loss of $1,397,353 was recorded in Q2 2025.
• The company completed the divestiture of a majority stake in NAYA Therapeutics, Inc. on June 2, 2025, retaining a minority position.
• Loss on disposition of NAYA Therapeutics was $1,534,517 for Q2 2025, and loss from discontinued operations of NAYA Therapeutics was $541,247 for Q2 2025.
• Telehealth capabilities and Platelet-Rich Plasma (PRP) therapy were launched at the Wisconsin clinic.
• A notice of allowance was received for a new patent for a modified INVOcell device, extending intellectual property protection through 2040.
• Clinical and embryology training support for INVOcell technology was expanded, and pricing was improved.
• Wisconsin Fertility Institute was recognized on Newsweek's List of Americas Best Fertility Clinics for 2025.

Sentiment

Score: 4

Explanation: While revenue saw a modest increase and strategic operational improvements were made, the significant widening of net loss and Adjusted EBITDA loss, coupled with substantial impairment and divestiture-related losses, indicates a challenging financial quarter. The strategic refocus is positive long-term, but short-term financial performance is weak.

Positives

• Achieved a new quarterly revenue record of $1,863,654, representing a 1% increase year-over-year.
• Successfully completed the divestiture of a majority stake in NAYA Therapeutics, Inc., allowing the company to refocus exclusively on its core fertility operations while retaining potential future benefits from NAYA's clinical development.
• Expanded service offerings at the Wisconsin clinic by launching telehealth capabilities and adding Platelet-Rich Plasma (PRP) therapy, enhancing patient care options.
• Received a notice of allowance for a new patent on a modified INVOcell device, extending intellectual property protection through 2040.
• Improved pricing and expanded training support for the innovative INVOcell technology, reinforcing its dual mission as an innovator and healthcare provider.
• The Wisconsin Fertility Institute was recognized on Newsweek's List of Americas Best Fertility Clinics for 2025, highlighting its quality and reputation.
• Recorded a gain on settlement of liability of $714,500.

Negatives

• Net loss from continuing operations widened significantly to $(3.2) million in Q2 2025, compared to $(2.2) million in Q2 2024.
• Adjusted EBITDA loss increased to $(587,230) in Q2 2025, up from $(509,623) in Q2 2024.
• Incurred a substantial impairment loss of $1,397,353 in Q2 2025.
• Reported a loss on disposition of NAYA Therapeutics of $1,534,517 for the quarter.
• Experienced a loss from discontinued operations of NAYA Therapeutics totaling $541,247 for the quarter and $16,452,562 for the six months ended June 30, 2025.
• Cost of revenue increased to $1,093,603 in Q2 2025 from $861,648 in Q2 2024.
• Incurred a loss from debt extinguishment of $692,270.

Risks

• Forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond the company's control, which may cause actual results, performance, or achievements to differ materially from anticipated results.
• Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in the company's filings at www.sec.gov.

Future Outlook

The company remains committed to maintaining a highly efficient and scalable operating structure while layering in complementary and accretive revenue-generating businesses and technologies. It also aims to benefit from NAYA Therapeutics' ongoing clinical development through its retained minority stake.

Management Comments

• "Following the decision in April 2025 to refocus exclusively on our fertility operations, we have made progress in driving growth and innovation in our existing operations and in taking key steps required for continued operating improvement moving forward."
• "Working collectively with our clinic operators, we have expanded our service offering to include new telehealth options and PRP therapy, demonstrating our commitment to quality patient-centered care."
• "We ramped up our training support for our INVOcell technology with clinicians and embryologists, in pursuit of our dual mission as an innovator of cutting-edge fertility solutions and healthcare services provider."
• "We remain committed to our goal of maintaining a highly efficient and scalable operating structure while layering in complementary and accretive revenue-generating businesses and technologies as we move forward."

Industry Context

The fertility industry continues to see advancements in assisted reproductive technologies. INVO Fertility's strategic shift to focus solely on fertility operations, coupled with the introduction of telehealth and PRP therapy, aligns with broader trends of expanding access to care and integrating innovative treatments. The recognition of its Wisconsin clinic by Newsweek underscores a focus on quality within a competitive landscape.

Comparison to Industry Standards

• Wisconsin Fertility Institute was recognized on Newsweek's List of Americas Best Fertility Clinics for 2025, indicating a high standard of care and reputation within the U.S. fertility clinic landscape.
• The company's INVOcell technology offers an intravaginal culture (IVC) procedure, which it believes can deliver comparable results at a fraction of the cost of traditional IVF, positioning it as a more affordable alternative to standard ART treatments.
• The IVC procedure is also presented as a significantly more effective treatment than intrauterine insemination (IUI).

Stakeholder Impact

• Shareholders: Experience increased net losses and Adjusted EBITDA losses in the short term, but may benefit from the strategic refocus on core fertility business and new patent protection in the long term.
• Patients: Benefit from expanded service offerings like telehealth and PRP therapy, and the recognition of the Wisconsin clinic for quality care.
• Employees: The strategic refocus might bring clarity and stability to the core fertility business.

Next Steps

• Continue to drive growth and innovation in existing fertility operations.
• Take key steps required for continued operating improvement.
• Maintain a highly efficient and scalable operating structure.
• Layer in complementary and accretive revenue-generating businesses and technologies.
• Potentially benefit from NAYA Therapeutics' ongoing clinical development through the retained minority stake.

Key Dates

Recommendation

The company is undergoing a strategic refocus by divesting its non-core NAYA Therapeutics business, which is a positive long-term move to streamline operations and concentrate on its core fertility services. Operational highlights like the new patent, telehealth, and PRP therapy additions, along with the Newsweek recognition, demonstrate progress in the core business. However, the significant widening of net loss and Adjusted EBITDA loss, driven by impairment and divestiture-related costs, indicates short-term financial weakness. While the strategic direction is sound, the current financial performance suggests a 'hold' position until there is clearer evidence of improved profitability and reduced losses from the refocused operations.

Keywords

Fertility, INVOcell, Assisted Reproductive Technology, ART, IVF, IVC, Healthcare Services, SEC Filing, Financial Results, Q2 2025, Patent, Telehealth, PRP Therapy, INVO Fertility, Nasdaq: IVF, Divestiture